Abstract
Background
Recently, a novel Helicobacter pylori stool antigen test (Testmate pylori antigen EIA) using monoclonal antibodies against H. pylori catalase has been developed commercially. This study assessed the diagnostic usefulness of the stool antigen test compared with a polyclonal enzyme immunoassay (HpSA test) after H. pylori eradication.
Methods
A total of 150 patients with H. pylori infection were treated by triple therapy with PPI and amoxicillin with either clarithromycin or metronidazole. H. pylori stool antigen was tested 4 and 8 weeks after eradication. The outcome of H. pylori eradication was assessed by urea breath test (UBT) 8 weeks after the end of therapy. Discordant results were followed by endoscopic examination.
Results
Of 150 patients enrolled, H. pylori status was negative in 122 cases and positive in 28 cases, assessed by the 13C-UBT. On the other hand, the monoclonal stool antigen test results were negative in 126 cases and positive in 24. The polyclonal stool test results were negative in 126 cases and positive in 22. The overall sensitivity and specificity of the monoclonal stool antigen test were 91.6% (95% CI 85.9–97.3%) and 98.4% (95% CI 97.3–99.5%). The overall sensitivity and specificity of the polyclonal stool antigen test were 87.0% (95% CI 86.9–94.0%) and 97.5% (95% CI 96.1–98.9%).
Conclusion
The new stool antigen test using monoclonal antibody is useful for the diagnosis of H. pylori eradication 4 weeks after the end of treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311–5.
Asaka M, Kato M, Sugiyama T, Satoh K, Kuwayama H, Fukuad Y, et al. Japan Helicobacter eradication Study Group. Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. J Gastroenterol. 2003;38:339–47.
Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, et al. The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol. 2005;100:1037–42.
Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of Helicobacter pylori infection; a systematic review. Helicobacter. 2004;9:347–68.
Suzuki N, Wakasugi M, Nakaya S, Kokubo N, Sato M, Kajiyama H, et al. Catalase, a specific antigen in the feces of human subjects infected with Helicobacter pylori. Clin Diagn Lab Immunol. 2002;9:784–8.
Kato C, Sugiyama T, Sato K, Saito S, Kudara N, Abiko Y, et al. Appropriate cut-off value of 13C-urea breath test after eradication of Helicobacter pylori infection in Japan. J Gastroenterol Hepatol. 2003;18:1379–83.
Masoero G, Lombardo L, Della Monica P, Vicari S, Crocilla C, et al. Discrepancy between Helicobacter pylori stool antigen assay and urea breath test in the detection of Helicobacter pylori infection. Digest Liver Dis. 2000;32:285–90.
Trevisani L, Sartori S, Galvani F, Rossi MR, Ruina M, Chiamenti C, et al. Evaluation of a new enzyme immunoassay for detecting Helicobacter pylori in feces: a prospective pilot study. Am J Gastroenteol. 1999;94:1830–3.
Ishihara S, Kaji T, Kawamura A, Rumi MA, Sato H, Okuyama T, et al. Diagnostic accuracy of a new non-invasive enzyme immunoassay for detecting Helicobacter pylori in stools after eradication therapy. Aliment Pharmacol Ther. 2000;14:611–4.
Odaka T, Yamaguchi T, Koyama H, Saisho H, Nomura F. Evaluation of Helicobacter pylori stool antigen test for monitoring eradication therapy. Am J Gastroenterol. 2002;97:594–9.
Tanaka A, Watanabe K, Tokunaga K, Hoshina S, Imase K, Sugano H, et al. Evaluation of Helicobacter stool antigen test before and after eradication therapy. J Gastroenterol Hepatol. 2003;18:732–8.
Ohara S, Kato M, Asaka M, Toyota T. Studies of 13C-urea breath test for diagnosis of Helicobacter pylori infection in Japan. J Gastroenterol. 1998;33:6–13.
Tokunaga K, Watanabe K, Tanaka A, Sugano H, Imase K, Ishida H, et al. Evaluation of 13C-urea breath test to confirm eradication of Helicobacter pylori (in Japanese with English abstract). J Jpn Soc Gastroenterol. 2005;102:183–9.
Ito M, Tanaka S, Kim S, Tahara K, Kawamura Y, Sumii M, et al. A combination of the Helicobacter pylori stool antigen test and urea breath test is useful for clinical evaluation of eradication therapy: a multicenter study. J Gastroenterol Hepatol. 2005;20:1241–5.
Nagahara A, Miwa H, Ogawa K, Kurosaaw A, Ohkura R, Iida N, et al. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rates with five-day therapy. Helicobacter. 2000;5:88–93.
Costa F, Mumolo MG, Bellini M, Romano MR, Manghetti M, Paci A, et al. Post-treatment diagnosis accuracy of a new enzyme immunoassay to detect Helicobacter pylori in stools. Aliment Pharmacol Ther. 2001;15:395–401.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Deguchi, R., Matsushima, M., Suzuki, T. et al. Comparison of a monoclonal with a polyclonal antibody-based enzyme immunoassay stool test in diagnosing Helicobacter pylori infection after eradication therapy. J Gastroenterol 44, 713–716 (2009). https://doi.org/10.1007/s00535-009-0069-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-009-0069-z